Lotte Biologics will attend three major biopharmaceutical conferences in October, seeking new contract manufacturing deals and broader global partnerships.
The company’s schedule includes CPHI Milan 2026 in Italy from Oct. 6-8, BioJapan 2026 in Yokohama from Oct. 7-9 and World ADC San Diego in California from Oct. 12-15.
At CPHI Milan, Lotte Biologics will showcase the large-scale commercial manufacturing capabilities of its Songdo Bio Campus and its dual-site production network spanning South Korea and the US. The company will also give presentations on bispecific antibodies and meet prospective clients and partners.
Digital manufacturing will take center stage at BioJapan. Lotte Biologics plans to present its manufacturing control system, digital twin technology and computational fluid dynamics simulations, which it says can improve production consistency and operational efficiency.
At World ADC San Diego, the company will highlight its proprietary antibody-drug conjugate platform and related technical capabilities as it seeks to expand its ADC business.
Lotte Biologics has secured four new contracts so far this year as it broadens its relationships with pharmaceutical and biotechnology companies.
In June, the company received approval to use Plant 1 at its Songdo Bio Campus, advancing its strategy to build a dual-site manufacturing network connecting Asia and North America.
yejinlim@heraldcorp.com
